Short Interest in Heartflow, Inc. (NASDAQ:HTFL) Increases By 19.6%

Heartflow, Inc. (NASDAQ:HTFL) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 5,453,610 shares, a growth of 19.6% from the February 12th total of 4,560,254 shares. Based on an average daily volume of 1,242,370 shares, the days-to-cover ratio is currently 4.4 days. Approximately 6.4% of the shares of the stock are sold short. Approximately 6.4% of the shares of the stock are sold short. Based on an average daily volume of 1,242,370 shares, the days-to-cover ratio is currently 4.4 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HTFL shares. Canaccord Genuity Group reissued a “buy” rating and set a $40.00 price target on shares of Heartflow in a research report on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Heartflow in a research note on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Price Performance

NASDAQ:HTFL traded up $1.54 on Tuesday, reaching $22.52. The company’s stock had a trading volume of 1,601,839 shares, compared to its average volume of 1,240,628. Heartflow has a 12-month low of $20.13 and a 12-month high of $41.22. The stock has a 50 day moving average price of $27.30 and a 200 day moving average price of $30.52.

Insider Buying and Selling

In other news, Director Julie A. Cullivan sold 9,122 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total value of $228,050.00. Following the completion of the sale, the director directly owned 27,291 shares in the company, valued at $682,275. This represents a 25.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the transaction, the chief executive officer owned 591,656 shares in the company, valued at approximately $16,246,873.76. The trade was a 3.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 2,117,674 shares of company stock valued at $59,052,646.

Institutional Trading of Heartflow

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow during the fourth quarter worth about $27,000. TFC Financial Management Inc. purchased a new stake in shares of Heartflow in the 3rd quarter valued at approximately $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Heartflow in the 4th quarter valued at approximately $45,000. Legal & General Group Plc acquired a new position in shares of Heartflow in the 3rd quarter worth approximately $59,000. Finally, Strs Ohio purchased a new position in shares of Heartflow during the 4th quarter worth approximately $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.